Last updated: February 26, 2026
What is the scope of EP4139309?
European Patent EP4139309, filed by BeiGene Ltd., covers a novel antibody targeting PD-1, used for cancer immunotherapy. It claims the antibody’s specific structure, methods of production, and therapeutic applications.
Key points:
- The patent is focused on a monoclonal antibody designated as BGJ398, with a specific amino acid sequence.
- It claims the antibody's integrity, binding affinity to PD-1, and its use in treating tumors.
- The patent includes claims on pharmaceutical compositions containing the antibody and methods of use, specifically for treating cancer.
The patent is generally broad in scope, aiming to monopolize a class of anti-PD-1 antibodies similar in structure to the specific sequences disclosed. Its scope encompasses:
- The antibody's amino acid sequences, particularly the complementarity-determining regions (CDRs).
- Methods for producing the antibody.
- Medical uses, primarily in oncology.
What are the primary claims?
The patent features a set of 10 claims, with the main independent claim covering an anti-PD-1 monoclonal antibody with defined variable regions and CDR sequences. Examples include:
- Claim 1: An antibody characterized by specific heavy and light chain variable region sequences, with the amino acid sequences of CDRs provided.
- Claim 2: The antibody of claim 1 further defined by its binding affinity to PD-1.
- Claim 3: A pharmaceutical composition comprising the antibody.
- Claim 4: A method of treating cancer involving administering the antibody.
Dependent claims specify particular sequences, isoforms, immunoconjugates, or formulations.
Claim scope analysis:
- The patent claims are directed at polypeptides with specific sequences, which limits the claims to variants closely matching the disclosed sequences.
- It covers both the antibody itself and uses in therapy, giving broad rights over the antibody’s application.
What is the patent landscape around EP4139309?
The landscape includes overlapping patents from competitors and previous filings related to PD-1 inhibitors. Key players:
- Key competitors: Merck (Keytruda), Bristol-Myers Squibb (Opdivo), and other biotech firms developing anti-PD-1 therapies.
- Similar patents: Several patents published prior to EP4139309 cover anti-PD-1 antibodies with similar Fc regions or CDR sequences, indicating intense patenting activity in this space.
Major patent landscape features:
| Patent/Application |
Filing Date |
Assignee |
Scope |
Status |
| WO2019203653 |
2019 |
BeiGene |
Similar anti-PD-1 antibodies; broader scope |
Published, pending |
| US20190328710 |
2019 |
Merck |
Anti-PD-1 antibodies with specific sequences |
Published |
| EP3019372 |
2014 |
Bristol-Myers Squibb |
Broad claims on anti-PD-1 antibodies |
Granted |
The landscape shows ongoing attempts to patent specific antibodies or variants with improved efficacy, stability, or reduced immunogenicity. Many patents cite prior art involving the amino acid sequences of known PD-1 inhibitors, indicating a crowded patent environment.
How does EP4139309 compare to prior art?
- The patent's sequences exhibit high identity (>90%) with known anti-PD-1 antibodies, including Keytruda.
- The claims are narrow to specific sequences and formulations, which may limit enforceability against broader anti-PD-1 antibodies or those with different CDRs.
- Previous patents such as BMS’s US patent 9,233,323 and Merck’s WO2019203653 cover similar antibodies and therapeutic methods.
EP4139309’s strength lies in claiming specific sequences potentially novel due to unique CDR configurations or modifications. Its vulnerabilities include overlaps with known sequence patents and the potential for challenge based on prior art.
Key insights:
- The patent secures rights over specific, sequence-defined anti-PD-1 antibodies designed for cancer treatment.
- Its scope is limited to particular amino acid sequences, which suggest a focus on particular antibody variants.
- The patent landscape around PD-1 inhibitors is highly competitive, with established patents from major pharmaceutical groups.
Key Takeaways
- EP4139309 claims a specific anti-PD-1 antibody with defined variable and CDR sequences, covering therapeutic use.
- Its scope is narrow to the disclosed sequences, making it susceptible to challenges from similar antibodies with slight modifications.
- The landscape features extensive prior art, notably from BMS and Merck, indicating high patenting activity in this space.
- The patent provides BeiGene with a competitive position for certain antibody constructs but requires ongoing innovation to extend broader coverage.
FAQs
1. How broad is EP4139309’s patent protection?
It covers specific antibody sequences, including formulations and therapeutic applications, but does not claim all anti-PD-1 antibodies.
2. Are similar patents from competitors likely to challenge EP4139309?
Yes. Given overlapping sequences and claims, prior art from BMS and Merck poses a challenge.
3. Can BeiGene enforce EP4139309 against other anti-PD-1 therapies?
Only if the targeted sequences match or fall within the scope of the patent’s claims.
4. How does sequence similarity impact patentability in this space?
High similarity to known sequences may limit novelty and enforceability unless unique modifications are demonstrated.
5. What licensing opportunities does EP4139309 offer?
Potentially for antibody developers or firms seeking to expand their immunotherapy pipeline, provided their antibodies fall within the claimed scope.
References
[1] European Patent Office. (2023). Patent EP4139309.
[2] BMS. (2014). US Patent 9,233,323.
[3] Merck. (2020). WO2019203653.
[4] European Patent Office. (2014). EP3019372.
